These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38736040)

  • 1. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.
    Dobner S; Bernhard B; Ninck L; Wieser M; Bakula A; Wahl A; Köchli V; Spano G; Boscolo Berto M; Elchinova E; Safarkhanlo Y; Stortecky S; Schütze J; Shiri I; Hunziker L; Gräni C
    ESC Heart Fail; 2024 Oct; 11(5):2759-2768. PubMed ID: 38736040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
    Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
    Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
    Rettl R; Mann C; Duca F; Dachs TM; Binder C; Ligios LC; Schrutka L; Dalos D; Koschutnik M; Donà C; Kammerlander A; Beitzke D; Loewe C; Charwat-Resl S; Hengstenberg C; Kastner J; Eslam RB; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):767-780. PubMed ID: 34788394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
    ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy.
    Uemura K; Ichikawa Y; Nagai S; Nishihara Y; Todo S; Oota E; Odajima S; Takeuchi K; Kintsu M; Fukuda T; Hisamatsu E; Hirata KI; Tanaka H
    Heart Vessels; 2024 Sep; 39(9):810-817. PubMed ID: 38743105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
    Tsai CH; Chao CC; Hsieh ST; Yu AL; Wu YA; Cheng MF; Lee MJ; Chou CH; Shun CT; Hsueh HW; Jyh-Ming Juang J; Tseng PH; Su MY; Lin YH
    Orphanet J Rare Dis; 2023 Sep; 18(1):289. PubMed ID: 37705003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
    Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy.
    Rettl R; Duca F; Binder C; Dachs TM; Cherouny B; Camuz Ligios L; Mann C; Schrutka L; Dalos D; Charwat-Resl S; Badr Eslam R; Kastner J; Bonderman D
    Amyloid; 2023 Mar; 30(1):127-137. PubMed ID: 36251806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis.
    Giblin GT; Cuddy SAM; González-López E; Sewell A; Murphy A; Dorbala S; Falk RH
    Eur Heart J Cardiovasc Imaging; 2022 Jul; 23(8):1029-1039. PubMed ID: 35274130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
    Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
    Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
    Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
    JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    Am J Cardiol; 2021 Feb; 141():98-105. PubMed ID: 33220323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis.
    Wu YA; Yu AL; Cheng MF; Lin LC; Lee MJ; Chou CH; Shun CT; Hsueh HW; Juang JJ; Tseng PH; Lin SP; Su MY; Chao CC; Hsieh ST; Tsai CH; Lin YH
    Ther Adv Chronic Dis; 2024; 15():20406223231222828. PubMed ID: 38223905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
    Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis.
    Kato S; Azuma M; Horita N; Utsunomiya D
    Tomography; 2024 Aug; 10(8):1303-1311. PubMed ID: 39195732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.
    Dobner S; Bernhard B; Asatryan B; Windecker S; Stortecky S; Pilgrim T; Gräni C; Hunziker L
    ESC Heart Fail; 2023 Feb; 10(1):397-404. PubMed ID: 36259276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.